Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 949-956

  Nguyen, Anthony ^a   Rosner, Andrea ^b,g   Milovanovic, Tatjana ^a   Hope, Christopher ^a   Planutis, Kestutis ^a   Saha, Baisakhi ^c   Chaiwun, Benjaporn ^d   Lin, Fritz ^e   Imam, S Ashraf ^f   Marsh, J Lawrence ^e   Holcombe, Randall F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Medical Research Institute   (United States)

^d CHIANG MAI UNIVERSITY   (Thailand)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Huntington Research Medical Institutes   (United States)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Breast cancer; LEF1; Transgenic mouse; Tumor cell invasion; Wnt

Indexed keywords

BETA CATENIN; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; LAMININ; LEF1 PROTEIN, HUMAN; LEF1 PROTEIN, MOUSE; LYMPHOID ENHANCER FACTOR 1; MATRIGEL; PROGESTERONE RECEPTOR; PROTEOGLYCAN; WNT PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; BREAST; CANCER INVASION; DOWN REGULATION; DRUG COMBINATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKEMIA CELL LINE; METABOLISM; MOUSE; PAGET NIPPLE DISEASE; PHYSIOLOGY; SIGNAL TRANSDUCTION; TIME; TRANSGENIC MOUSE; TUMOR CELL LINE; UDDER; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; BREAST; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; COLLAGEN; DOWN-REGULATION; DRUG COMBINATIONS; ESTRADIOL; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; JURKAT CELLS; LAMININ; LYMPHOID ENHANCER-BINDING FACTOR 1; MAMMARY GLANDS, ANIMAL; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PROTEOGLYCANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UP-REGULATION; WNT PROTEINS;

EID: 33644828252     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.949     Document Type: Article

References (51)

1. Cadigan KM and Nusse R: Wnt signaling: a common theme in animal development. Genes Dev 11: 3286-3305, 1997.
2. Bhanot P, Brink M, Samos CH, Hsieh J-C, Wang Y, Macke JP, Andrew D, Nathans J and Nusse R: A new member of the Frizzled family from Drosophila functions as a Wingless receptor. Nature 282: 225-230, 1996.
3. Yang-Snyder J, Miller JR, Brown JD, Lai C-J and Moon RT: A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr Biol 6: 1302-1306, 1996.
4. He X, Saint-Jeannet J-P, Wang Y, Nathans J, Dawid I and Varmus H: A member of the Frizzled protein family mediating axis induction by Wnt5a. Science 275: 1652-1654, 1997.
5. Theisen H, Purcell J, Bennett M, Kansagara D, Syed A and Marsh JL: Dishevelled is required during wingless signaling to establish both cell polarity and cell identity. Development 120: 347-360, 1994.
6. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R and Birchmeier W: Functional interaction of Bcatenin with the transcription factor LEF1. Nature 382: 638-642, 1996.
7. Van de Wetering M, Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J, Ypma A, Hursh D, Jones T, Bejsovec A, Peifer M, Mortin M and Clevers H: Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88: 789-799, 1997.
8. Riese J, Yu X, Munnerlyn A, Eresh S, Hsu S-C, Grosschedl R and Bienz M: Lef1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic. Cell 88: 777-787, 1997.
9. Brannon M, Gomperts M, Sumoy L, Moon RT and Kimelman D: A β-catenin-XTCF3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus. Genes Dev 11: 2359-2370, 1997.
10. Cavallo R, Rubenstein D and Peifer M: Armadillo and dTCF: a marriage made in the nucleus. Curr Opin Genet Dev 7: 459-466, 1997.
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, Da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
12. Testu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
13. Stutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestall R and Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF1 pathway. Proc Natl Acad Sci 96: 5522-5527, 1999.
14. Bienz M: TCF: transcriptional activator or repressor? Curr Opin Cell Biol 10:366-372, 1998.
15. Nusse R and Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31: 99-109, 1982.
16. Devanesan P, Santen RJ, Bocchifuso WP, Korach KS, Rogan EG and Cavalieri E: Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-alpha knock-out (ERKO)/Wnt-2 mice: implications for initiation of mammary tumors. Carcinogenesis 22: 1573-1576, 2001.
17. Bocchinfuso WP and Korach KS: Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 2: 323-334, 1997.
18. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD and Chodosh LA: Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17: 488-501, 2003.
19. Michaelson JS and Leder P: Beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 20: 5093-5099, 2001.
20. Brown AM: Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res 3: 351-355, 2001.
21. Berstein I and Brown AMC: Wnt genes and breast cancer. In: Breast Cancer: Molecular Genetics, Pathogenesis and Therapeutics. Bowcock AM (ed). Humana Press, Inc., Totowa, NJ, 1997.
22. Milovanovic T, Planutis K, Nguyen A, Marsh HL, Lin F, Hope C and Holcombe RF: Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol 25: 1337-1342, 2004.
23. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG and Hung MC: Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97: 4266, 2000.
24. Barker N, Huls G, Korinek V and Clevers H: Restricted high level expression of TCF4 protein in intestinal and mammary gland epithelium. Am J Pathol 154: 29-35, 1999.
25. Van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, Bruhn L and Grosschedl R: Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev 8: 2691-2703, 1994.
26. Hovanes K, Munguia JE, Truong T, Milovanovic T, Li TWH, Marsh JL, Holcombe RF and Waterman ML: Beta-cateninsensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28: 53-57, 2001.
27. Murakami T, Toda S, Fujimoto M, Oktsuki M, Byers HR, Etoh T and Nakagawa H: Constitutive activation of Wnt/β-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys Res Commun 288: 8-15, 2001.
28. Lane TF and Leder P: Wnt- 10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 15: 2133-2144, 1997.
29. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD and Seldin DC: Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20: 3247-3257, 2001.
30. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE and Cardiff RD: Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 161: 1087-1097, 2002.
31. Cardiff RD, Sinn E, Muller W and Leder P: Transgenic oncogene mice. Tumor phenotype predicts genotype. Am J Pathol 139: 495-501, 1991.
32. Muller WJ, Sinn E, Pattengale PK, Wallace R and Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115,1988.
33. Guy CT, Cardiff RD and Muller WJ: Activated neu induces rapid tumor progression. J Biol Chem 271: 7673-7678, 1996.
34. Siegel PM, Dankort DL, Hardy WR and Muller WJ: Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14: 7068-7077, 1994.
35. Yang C, Ionescu-Tiba V, Burns K, Gadd M, Zukerberg L, Louis DN, Sgroi D and Schmidt EV: The role of the cyclin D1dependent kinases in ErbB2-mediated breast cancer. Am J Pathol 164: 1031-1038,2004.
36. Andrecheck ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD and Muller WJ: Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 28: 3444-3449, 2000.
37. Cheung ATW, Young LJT, Chen PCY, Barry PA, Muller WJ and Cardiff RD: Microcirculation and metastasis in a new mouse mammary tumor model system. Int J Oncol 11: 69-77, 1997.
38. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235: 177-182, 1987.
39. Allegra JC and Lippman ME: Estrogen receptor status and the disease-free interval in breast cancer. Recent Results Cancer Res 71: 20-25, 1980.
40. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z, Tan LK, Rosen JM and Varmus HE: Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100: 15853-15858,2003.
41. Takata M, Fujimoto A, Aoki H, Hatta N, Ooi A and Takehara K: ErbB-2 overexpression but no activation of beta-catenin gene in extramammary Paget's disease. J Invest Dermatol 113: 258-262, 1999.
42. Musgrove EA: Wnt signaling via the epidermal growth factor receptor: a role in breast cancer? Breast Cancer Res 6: 65-68, 2004.
43. Willert J, Epping M, Pollack JR, Brown PO and Nusse R: A transcriptional response to Wnt protein in human embryonic carcinoma cells. Dev Biol 2: 8-14, 2002.
44. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T and Truong T: Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon cancer. Mol Pathol 55: 220-226, 2002.
45. Katoh M: Expression and regulation of Wntl in human cancer: up-regulation of Wntl by beta-estradiol in MCF-7 cells. Int J Oncol 22: 209-212, 2003.
46. Saitoh T, Mine T and Katoh M: Up-regulation of frizzled-1 (FZD10) by beta-estradiol in MCF7 cells and by retinoic acid in NT2 cells. Int J Oncol 20: 117-120, 2002.
47. Kirikoshi H and Katoh M: Expression and regulation of Wnt10b in human cancer: up-regulation of Wnt10b in MCF-7 cells by beta-estradiol and down-regulation of Wnt10b in NT2 cells by retinoic acid. Int J Mol Med 10: 507-511, 2002.
48. Robinson GW, Hennighausen L and Johnson PF: Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev 14: 889-894, 2000.
49. Vilmos P, Gaudenz K, Hegedus Z and Marsh JL: The Twisted gastrulation family of proteins, together with the IGFBP and CCN families, comprise the TIC super-family of cysteine-rich secreted factors. Mol Pathol 54: 317-323, 2001.
50. Zoubine MN, Banerjee S, Saxena NK, Campbell DR and Banerjee SK: WISP2: a serum-inducible gene differentially expressed in human normal breast epithelial cells and in MCF7 breast tumor cells. Biochem Biophys Res Commun 282: 421-425, 2001.
51. Inadera H, Hashimoto S, Dong HY, Suzuki T, Nagai S, Yamashita T, Toyoda N and Matsushima K: WISP2 as a novel estrogen-responsive gene in human breast cancer cells. Biochem Biophys Res Commun 275: 108-114, 2000.